Emerging Drug Developer: GlobeImmune

Emerging Drug Developer: GlobeImmune

Platform companies that can show promise against a number of diseases have been flourishing, and GlobeImmune is at a critical point in its effort to join that crowd. With a second therapy slated to start a mid-stage trial and an important set of data scheduled to land next year, the Colorado biotech is one short, but vitally important, step away from a juncture that could well spawn new business opportunities. A fresh funding round will take it through 2008, and into a new phase of development. Article

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.